Sanofi and Regeneron cut list price of cholesterol drug by 60 pct

By

By Michael Erman

NEW YORK (Reuters) - Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive PCSK9 inhibitor Praluent (alirocumab) by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

The new list price for Praluent will be $5,850 a year, matching the price Amgen set when it lowered the list of its competing cholesterol-lowering drug, Repatha (evolocumab), in October.

Sanofi and Regeneron said they expect the lower-priced Praluent to be available for pharmacies to order in early March. They said the new price should improve patient access and result in lower out-of-pocket costs for U.S. consumers.

Sales of both of the injectable biotech drugs have been severely constrained by onerous roadblocks to patient access put up by insurers looking to limit spending on the expensive medications.

They were approved in 2015 with initial list prices of more than $14,000 a year.

In March of last year, Regeneron and Sanofi said that they would be willing to charge less for their drug if insurers agreed to reduce barriers for high-risk heart patients.

A few months later they struck a deal with Express Scripts, now part of Cigna Corp, to make the drug available to that company's customers at a price in the range of $4,500 to $6,600 a year.

The United States, which leaves drug pricing to market competition, has higher prices than in other developed countries, where governments directly or indirectly control costs. That makes it by far the world's most lucrative market for manufacturers.

Congress has been targeting the pharmaceutical industry over the rising cost of prescription drugs for U.S. consumers, particularly since Democrats took over the House of Representatives in January.

Executives from at least six drugmakers plan to testify at a Senate hearing on rising prescription drug prices later this month.

Drug pricing is also a top priority of the administration of President Donald Trump, who had made it a central issue of the 2016 presidential campaign.

Related Articles

U.S. Medicare plans to track CAR-T cancer therapy outcomes

By Deena Beasley (Reuters) - The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including a Read More »

Smartphone app promising for postop care after pediatric tonsillectomy

By Marilynn Larkin NEW YORK (Reuters Health) - Families and caregivers found a smartphone app helpful for communicating with a physician after their child's tonsillectomy, in a pilot study. Dr. S. Read More »

Neoadjuvant anti-PD-1 immunotherapy may improve glioblastoma outcomes

By Will Boggs MD NEW YORK (Reuters Health) - Neoadjuvant immunotherapy with anti-PD-1 agents may improve outcomes in patients with resectable or recurrent glioblastoma, researchers report. "The Read More »